Please login to the form below
Novavax
This page shows the latest Novavax news and features for those working in and with pharma, biotech and healthcare.
Novavax initiates phase 2 combination COVID-19/flu vaccine study
Novavax has announced the initiation of a phase 2 trial for its combination COVID-19/influenza and stand-alone influenza vaccine candidates. ... Stanley Erck, president and chief executive officer, Novavax, said: "We're encouraged by the initiation of
Latest news
-
Novavax’s COVID-19 vaccine receives MHRA approval for use as a booster
Novavax’s protein-based vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralising antibodies. ... A number of countries also have policy recommendations allowing use of the
-
Novavax’s BA.1 COVID-19 booster shows strong immune response in phase 3 trial
Novavax has announced topline results from a phase 3 trial of its COVID-19 vaccines, showing that its Omicron-adapted BA.1 vaccine candidate, NVX-CoV2515, met the primary strain-change ... Additionally, the study showed no benefit for the Novavax
-
Novavax’s COVID-19 vaccine candidate approved for emergency use by FDA as a booster
Novavax’s COVID-19 vaccine, Adjuvanted (NVX-CoV2373) has been granted emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) as a booster in adults 18 years and ... strain. Stanley Erck, president and chief executive officer,
-
Novavax’s COVID-19 vaccine candidate receives EC approval for use as a booster
Novavax’s protein-based vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralising antibodies. ... In the Novavax-sponsored trials, following the booster, local and systemic
-
Novavax’s COVID-19 vaccine candidate receives CHMP recommendation for use as a booster
Novavax’s COVID-19 vaccine – Nuvaxovid – has been recommended for expanded conditional marketing authorisation (CMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for ... In the Novavax-sponsored
More from news
Approximately 26 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
Developing a COVID-19 vaccine
The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
-
Deal Watch table for June 2013
30. Isconova / Novavax. Acquisition. Proprietary vaccine adjuvant technology. 30. Unless noted, transactions are for global rights.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
